WHO Drug Information Vol. 25, No. 2, 2011

WHO Drug Information Vol. 25, No. 2, 2011 Proposed INN: List 105patéclizumabpateclizumabimmunoglobuline G1-kappa, anti-[Homo sapiens LTA (lymphotoxinealpha, TNFSF1, membre 1 de la superfamille du facteur de nécrosetumorale, LT)], anticorps monoclonal humanisé;chaîne lourde gamma1 (1-447) [VH humanisé (Homo sapiensIGHV3-74*01 (76.50%) -(IGHD)-IGHJ5*01) [8.9.11] (1-118) -Homosapiens IGHG1*03 CH1 R120>K (215), CH3 K130>del (119-447)],(221-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPAhumanisé (Homo sapiens IGKV1-39*01 (88.40%) -IGKJ1*01) [6.3.9](1'-107') -Homo sapiens IGKC*01 (108'-214')]; dimère (227-227":230-230")-bisdisulfureimmunomodulateurinmunoglobulina G1-kappa, anti-[LTA de Homo sapiens (linfotoxinaalfa, TNFSF1, miembro 1 de la superfamilia del factor de necrosistumoral, LT)], anticuerpo monoclonal humanizado;cadena pesada gamma1 (1-447) [VH humanizada (Homo sapiensIGHV3-74*01 (76.50%) -(IGHD)-IGHJ5*01) [8.9.11] (1-118) -Homosapiens IGHG1*03 CH1 R120>K (215), CH3 K130>del (119-447)],(221-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPAhumanizada (Homo sapiens IGKV1-39*01 (88.40%) -IGKJ1*01)[6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dímero (227-227":230-230")-bisdisulfuroinmunomodulador1202526-59-7Heavy chain / Chaîne lourde / Cadena pesadaEVQLVESGGG LVQPGGSLRL SCAASGYTFT SYVIHWVRQA PGKGLEWVGY 50NNPYNAGTNY NEKFKGRFTI SSDKSKNTAY LQMNSLRAED TAVYYCSRPT 100MLPWFAYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPG 447Light chain / Chaîne légère / Cadena ligeraDIQMTQSPSS LSASVGDRVT ITCRASQAVS SAVAWYQQKP GKAPKLLIYS 50ASHRYTGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQE SYSTPWTFGQ 100GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200LSSPVTKSFN RGEC 214Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H 22-96 145-201 262-322 368-42622''-96'' 145''-201'' 262''-322'' 368''-426''Intra-L 23'-88' 134'-194'23'''-88''' 134'''-194'''Inter-H-L 221-214' 221''-214'''Inter-H-H 227-227'' 230-230''N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación298, 298''peginterferonum lambda-1a #peginterferon lambda-1a pegylated interferon lambda-1; pegylated interleukin 29;N-{3-[α-methylpoly(oxyethylene)oxy]propyl}-L-methionyl{[171-serine]human interleukin-29 (IFN-λ-1)-(7-181)-peptide}antiviralpeginterféron lambda-1ainterféron lambda-1 pégylé; interleukine-29 pégylée;N-{3-[α-méthylpoly(oxyéthylène)oxy]propyl}-L-méthionyl{[171-sérine]interleukine-29 humaine (IFN-λ-1)-(7-181)-peptide}antiviral187